Hypercalcemia: an evidence-based approach to clinical cases

Area of Science:

• Endocrinology
• Oncology
• Nephrology

Background:

• Hypercalcemia, often caused by primary hyperparathyroidism or malignancy, presents diagnostic challenges.
• Primary hyperparathyroidism typically involves lower calcium levels and chronic symptoms, unlike the acute, severe presentation of malignancy-associated hypercalcemia.
• Key differences include the presence of kidney calculi and metabolic acidosis in hyperparathyroidism, and anemia in malignancy.

Purpose of the Study:

• To differentiate hypercalcemia causes, focusing on primary hyperparathyroidism versus malignancy.
• To outline characteristic clinical and laboratory findings for each condition.
• To review current treatment approaches for hypercalcemia.

Main Methods:

• Comparative analysis of clinical features and laboratory findings in hypercalcemia.
• Emphasis on parathyroid hormone (PTH) assay as a key diagnostic tool.
• Review of established hypercalcemia management protocols.

Main Results:

• Primary hyperparathyroidism: lower serum calcium (<12 mg/dL), longer duration (>6 months), kidney calculi, metabolic acidosis, osteitis fibrosa cystica, no anemia.
• Malignancy-associated hypercalcemia: rapid onset, higher calcium levels, severe symptoms, marked anemia, absence of kidney calculi or metabolic acidosis.
• Elevated PTH levels confirm hyperparathyroidism; suppressed PTH suggests other causes.

Conclusions:

• Parathyroid hormone assay is crucial for distinguishing hyperparathyroidism from malignancy-induced hypercalcemia.
• Initial treatment involves hydration and loop diuretics if needed.
• Long-term management of severe hypercalcemia requires bisphosphonates, with specific agents like zoledronic acid or pamidronate recommended.